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Abstract In Alzheimer disease (AD) the microtubule associated 
protein (MAP) tau is hyperphosphorylated at several sites. In the 
present study, like AD tau, tau in the human neuroblastoma 
SH-SY5Y was found to be hyperphosphorylated, at Ser-199/202, 
Thr-231, Ser-396 and Ser-404. However, in contrast to AD, the 
tau in SY5Y cells was not hyperphosphorylated at Ser-235 and 
there was only one tau isoform. Quantitative analysis revealed 
that approximately 80% of the SY5Y- tau was phosphorylated 
at Ser-199/202. The phosphorylated tau was deposited in peri- 
karya and processes of the cells whereas most of the 
unphosphorylated (at Ser-199/202) tau was localized in the nu- 
cleus. Tau from the cell lysates did not bind to taxol-stabilized 
microtubules. In contrast, MAPlb and MAP2 from cell lysates 
bound to stabilized microtubules in vitro and were associated to 
the microtubule network in situ. Phosphorylation of tau at high 
levels, its inactivity with microtubules and its accumulation in 
SY5Y cells provide for the first time a cell model of cytoskeletal 
changes een in AD. 
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I. Introduction 
A major biochemical abnormality in the Alzheimer disease 
(AD) brain is the abnormally hyperphosphorylated microtu- 
bule associated protein (MAP) tau [1-3]. The abnormal tau is 
the major protein subunit of the paired helical filament (PHF) 
[1,3 5] and it is in this form that tau accumulates a neurofibril- 
lary tangles in the perikaryon, in the neuropil threads [6] of the 
neuropil and in the dystrophic neurites of neuritic (senile) pla- 
ques. In addition, the abnormal tau also accumulates in normal 
appearing neurons in amorphous aggregates intermixed with a 
few short PHF, forming the so-called 'stage 0' tangles [7,8]. 
Unlike the mature neurofibrillary tangles, the stage 0 tangles 
are only poorly argentophilic and are not stained by thioflavin- 
S or Congo red. Recently, hyperphosphorylated au(AD P-tau) 
was isolated from AD brain that, although not ubiquitinated 
and not polymerized into PHF, sediments at 27,000 to 
200,000 x g, is soluble in buffers after denaturation with urea 
and has phosphate levels comparable to those of the PHF [9]. 
Furthermore, like PHF, the AD P-tau is phosphorylated at 
several sites and does not promote in vitro microtubule assem- 
bly unless dephosphorylated with alkaline phosphatase [10,11]. 
Previously it was not known whether the altered solubility 
characteristics of AD-P tau and its negative ffect on microtu- 
bule assembly observed in vitro also occur in the living cell. In 
the present study we show that approximately 80% of tau in the 
human neuroblastoma cell line SH-SY5Y is hyperphos- 
phorylated at the Tau-1 epitope, and, like the AD P-tau is 
hyperphosphorylated at least at three other sites. Furthermore, 
the abnormal tau, like in AD, accumulates in the cell body and 
does not seem to be biologically active since it is neither associ- 
ated to the cellular microtubule network in situ nor in vitro 
binds to taxol-stabilized microtubules. However, unlike the ab- 
normal tau in AD, the SY5Y-tau is not phosphorylated at 
Ser-235. The microtubule network itself seems to be intact in 
the SY5Y cells and is supported by MAP2 and MAPlb.  
2. Materials and methods 
2.1. Cells and proteins 
SH-SY5Y human euroblastoma cells were obtained from Dr. June 
L. Biedler (Sloan Kettering Institute, NY). Cells were cultured up to 
about 70% confluence in 35-mm diameter dishes employing D-MEM/ 
F-12 medium (Gibco BRL, Gaithersburg, MD) (5% CO2; 37°C) supple- 
mented with 5% fetal calf serum, 100 IU/ml of penicillin, and 100/lg/ml 
of streptomycin. The cells were fed every three days. In some cases the 
cells were deprived of nutrient by keeping them in the same medium 
without feeding for two to four additional days. For Western blots and 
immunoassays, the cells were collected from each dish by pipetting up 
and down, were lysed in 100 ¢tl of 2% SDS/ct-mercaptoethanol, heated 
in a boiling water bath for 5 min and sonicated in a water bath for 10 
min. The protein concentrations were assayed by the modified Lowry 
method of Bensadoun and Weinstein [12]. In some cases tau was im- 
munoprecipitated from the cell lysates with polyclonal anti-tau anti- 
body, 92e [13] bound to agarose linked protein G (Pierce, Rockford, 
IL). 
Tau protein from normal human brain and soluble abnormally 
phosphorylated tau from Alzheimer disease (AD P-tau) brain were 
prepared as previously described [9]. Sources and dilutions of anti-tau 
antibodies employed are shown in Table 1. Other antibodies employed 
were DMIA (anti-~ tubulin, 1:1000, Sigma, St. Lois, MO), YLI/2 
(anti-tyrosinated tubulin, 1:500, Sera Lab, Westbury, NY), anti- 
MAPlb (1:400, Amersham, Arlington Heights, IL), and anti-MAP2 
[14] (1:1000; a gift from Dr. R.B. Vallee, Shrewsbury, MA). Im- 
munoblots were performed as previously described [1]. 
To determine the isoforms of tau protein in SY5Y cells, the cell 
lysates were first dialysed against 100 mM Tris, pH 8.0, 1 mM EGTA, 
0.1 mM EDTA, 1 mM MgCI2, and protease inhibitors (5 ¢tg/ml aprot- 
inin, 5/.tg/ml Leupoptin, 2¢tg/ml pepstatin and 1 mM PMSF) and then 
treated with 100 U/ml alkaline phosphatase (Boehringer-Mannheim, 
Indianapolis, IL) at 37°C for 8 h. Recombinant tau 23 and 24 [15] 
expressed in E. coli were employed as Mr markers. 
2.2. Radioimmuno-dot-blot assay 
Triplicate samples of cell lysates containing 1 ,ug and 3/lg of total 
protein in 5 ¢tl were applied to nitrocellulose membranes (Schleicher 
and Schuell, Keene, NH) and dried at 37°C for 30 min. The tau contents 
were determined using Tau-I and ~25-1abeled anti-mouse IgG (Amer- 
sham, Arlington Heights, IL) with or without prior dephosphorylation 
of the protein on the membrane with alkaline phosphatase as previously 
described [16]. Purified recombinant tau 39 was employed for the stand- 
ard curve in the immunoassay. 
*Corresponding author. Fax: (1) (718) 494-1080. 
2.3. Indirect immunofluorescence microscopy 
SH-SY5Y cells were cultured in Lab-Tec slides (Nunc, Naperville, 
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IL) and, fixed in 4% formaldehyde in 100 mM HEPES, pH 6.8, 0.2% 
Triton X-100, 5 mM EGTA and 10 mM MgC12 [17]. The cells were 
post-fixed with -20°C methanol for 5 min, washed with phosphate 
buffered saline, blocked in 2% BSA/Tris buffered saline and incubated 
with primary antibodies followed by FITC-labeled secondary antibod- 
ies (Cappel, Durham, NC). The slides were mounted in Vector-Shield 
mounting media (Vector Lab. Inc., Burlingame, CA). Fixation of the 
cells in -20°C methanol instead of formalin resulted in immunostaining 
of comparable intensity. 
2.4. Taxol stabilized microtubules 
Twice cycled microtubules from rat brain [18] were cold-disassem- 
bled and employed to prepare MAP-free tubulin by phosphocellulose 
chromatography [19]. Taxol stabilized microtubules were then prepared 
by incubating 1mg tubulin/ml with 20/.tM Taxol at 37°C for 30 min. 
2.5. Microtubule binding assay 
The cells (~ 1 x 107) were lysed in 100 mM PIPES, pH 6.8, 0.1% Triton- 
X 100, 2 mM MgCI> 1 mM EGTA, 0.1 mM EDTA, 10 mM sodium 
fluoride, 1 mM sodium vanadate and protease inhibitors (see above), 
and centrifuged at 200,000 x g for 30 min. The supernatant (900/.tg 
protein) was incubated with 100/lg of taxol-stabilized microtubules and 
10/IM taxol at 37°C for 30 min and centrifuged at 70,000 xg  for 45 
min. The supernatant containing the unbound proteins and the pellet 
of stabilized microtubules and microtubule bound proteins were ana- 
lyzed by immunoblots. 
3. Results 
3.1. Tau in S Y5 Y cells is hyperphosphorylated at several sites 
Western blots developed with anti-tau antibodies demon- 
strated the expression of tau protein in SH-SY5Y human neu- 
roblastoma cells (Fig. 1). AT8 (P Ser-199/202), PHF-1 (P Ser- 
396), SMI-31 (P Ser-396 and P Ser-404) and M4 (P Thr-231) 
antibodies all of which react with phosphorylated epitopes of 
tau, but not with normal  tau, reacted with tau in SY5Y cell 
lysate. Tau-1 ant ibody that only recognizes its epitope if it is 
not phosphorylated (Ser-199/Ser-202), stained only one faint 
band on the Western blot but strongly reacted with a series of 
polypeptides in the 51~53 kDa range after pretreatment of the 
blots with alkaline phosphatase. In contrast, ant ibody SMI33 
(Ser-235) stained the tau polypeptides, and the pretreatment of
the blots with alkaline phosphatase had no apparent effect on 
the intensity, indicating that SY5Y-tau is not phosphorylated 
at Ser-235 (data not shown). SY5Y-tau dephosphorylated in 
vitro was stained as a single band and co-migrated with the 
recombinant tau 23, the human tau isoform with three repeats 
of tubulin binding domains and no N-terminal inserts (same as 
fetal tau) [15]. 
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Fig. 1. Phosphorylation sites and M r of SH-SY5Y tau. (A) 100 pg of 
cell lysates were applied to each lane; AD P-tau was used at 2 pg/lane. 
*Indicates alkaline phosphatase treatment of the Western blot prior to 
the application of the antibodies. In the case of SMI31 and M4, samples 
immunoprecipitated with tau antibody 92e were applied to avoid non- 
specific staining. Phosphorylation of SY5Y-tau at Ser-199/202 is indi- 
cated by the reaction with AT8 as well as by a marked increase in tau 
staining with Tau-1 after dephosphorylation of the blot. The reaction 
of PHF-1 and SMI 31 with SY5Y tau indicates phosphorylation at
Ser-396/404. The reaction of M4 with SY5Y-tau indicates phosphoryl- 
ation of tau at Thr-231. Not shown in this figure, SY5Y tau is not 
significantly phosphorylated at Ser-235 since there was no increase of 
tau staining with antibodies SMI33 after dephosphorylation f the 
blots. (B) 50/tg of cell lysates dephosphorylated in vitro were applied 
to lane 1 and 0.2 pg/each of recombinant tau 23 and 24 were applied 
to lanes 2 and 3 respectively. Apparent M r weight of tau 23 and 24 are 
48 kDa and 52 kDa, respectively [15]. Dephosphorylated SY5Y-tau 
(lane 1) was visualized as a single band that corresponded totau 23, the 
shortest human tau isoform. SY5Y-tau in the untreated cell lysate 
(100,ug) in lane 4 has slower mobility than dephosphorylated SY5Y tau 
in lane 1. 
3.2. Most  o f  the tau is phosphorylated at Ser-199/202 
To determine what percentage of tau was hyper- 
phosphorylated in the SY5Y cells, levels of tau in cell lysate 
were determined by radio immuno-dot-b lot  assay using Tau-1 
with and without pretreatment of the blots with alkaline phos- 
phatase. A 5-6-fold increase in the tau levels after 
dephosphorylat ion was observed (Fig. 2), while the levels o f tau  
isolated from control brains were not affected by the phosphat-  
ase treatment (data not shown). F rom three independent exper- 
iments the percentage of tau abnormal ly phosphorylated at the 
Table 1 
Source and dilution of the tau antibody 
Ab Type Epitope Phosphorylated Dilution References 
(P)/Not-Phosphorylated (N)
Tau antibodies 
Tau-1 mono Ser 199/202 N 1 : 50,000 34 
AT8 mono Ser 199/202 P 1:50 35 
M4 mono Thr 231 P 1 : 2,000 36 
SM133 mono Ser 235 N 1 : 500 37 
SM 131 mono Ser 269/404 P 1 : 100 37 
PHF1 mono Ser 396 P 1 : 100 38 
92e poly - - 1 : 5* 13 
*Dilution used for immunoprecipitation. 
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Fig. 2. Levels of tau hyperphosphorylated at Ser- 199/202. Levels of tau 
in SY5Y lysates were estimated by comparison with defined amounts 
of recombinant tau 39. Blots treated (T. tau -- total tau) or untreated 
with alkaline phosphatase (N" tau = tau not phosphorylated at the Tau- 
1 epitope) were exposed to Tau-1 antibody [125I]anti-mouse IgG. The 
value for P. tau (phosphorylated at the Tau-1 epitope) was determined 
by subtraction ofthe value obtained for N. tau from that of T. tau. The 
data were obtained from three independent experiments. 
Tau-1 epitope was determined to be 82% + 10 of the total tau 
level of 1.3 + 0.2 ng//tg lysate protein. 
3.3. Phosphorylated tau accumulates in the cytoplasm in SY5 Y 
cells 
The association of tau to the microtubule network in SY5Y 
neuroblastoma cells was examined by indirect immunofluores- 
cence (Figs. 3, 4). A dense microtubule network was seen with 
anti-tubulin antibody in cell bodies and neurites, (Fig. 3d) 
whereas no fibrillar staining by Tau-1, AT8 or PHF-1 antibod- 
ies (Fig. 3a-c) was observed. Tau-1 labeling was seen as several 
bright dots in the nucleus while in the cytosol only a faint 
background staining was observed (Fig. 3a). In contrast, strong 
immunoreactivity of AT8 (P Ser-199/202) was found in the 
cytoplasm and in the several neuronal processes (Fig. 3b). No 
binding to fibrous structures was apparent. PHF-1 (P Ser-396) 
stained brightly fluorescent deposits along the cytoplasmic 
seam around the unstained nucleus (Fig. 3c). Mitotic cells were 
most intensely labeled with PHF-1. In contrast o tau, anti- 
MAPlb and anti-MAP2 antibodies tained the intracellular 
fibrous network, and in addition several neuronal processes of 
the SY5Y cells (Fig. 3e). 
When cells were cultured at suboptimal conditions, i.e. with- 
out changing the medium for 5 days to 7 days instead of 3 days, 
large accumulations of phosphorylated tau were observed in 
the cytoplasm, that were strongly immunoreactive with PHF-1 
and AT8 (Fig. 4a,b). Apparently, the microtubule network of 
these cells was intact since it was labeled both with mAb DMIA 
to cz tubulin and with YL 1/2 antibody to the labile microtubule 
population (Fig. 4c,d). 
Fig. 3. Immunofluorescent staining of formalin fixed SH-SY5Y cells with antibodies to (a-c) tau: (a) Tau-1, (b) AT-8, and (c) PHF-1, (d) tubulin 
and (e) MAPlb. The microtubule network was stained with antibodies to tubulin, MAPlb and, not shown here, MAP2. No microtubule staining 
was observed with any of the tau antibodies. 
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Fig. 4. Immunofluorescent staining of SH-SY5Y cells that were for 5 
days in culture without medium change. Antibodies to hyper- 
phosphorylated tau: AT-8 (a), PHF-1 (b), and to tubulin: DM1A (c), 
YL1/2 (d) were employed. The microtubule network appeared slightly 
less dense than in Fig. 3 while tau aggregation appeared more promi- 
nent. Not shown in this figure, a similar pattern was observed after 7 
days of nutrient deprivation. 
3.4. Most SY5Y  tau does not bind to microtubules 
To determine whether tau was biologically active in binding 
to microtubules, the 200,000 x g extract of the SY5Y cells was 
incubated with taxol-polymerized microtubules, and the micro- 
tubule bound and unbound proteins were separated into pellet 
and supernatant, respectively. The immunoblots of these frac- 
tions revealed that almost all of MAPlb and MAP2 bound but 
most of the SY5Y-tau did not bind to the microtubules 
(Fig. 5). 
4. Discussion 
In Alzheimer disease 75-85% of the MAP tau, including all 
six isoforms, is altered both in its degree of phosphorylation 
and its solubility-characteristics [1,3,9,13,16]. In vitro studies 
have shown that the abnormal hyperphosphorylation of tau 
renders it biologically inactive [10,11,20]. In the present study 
we show for the first time that tau in SY5Y cells is 
phosphorylated at five of six of the abnormal phosphorylation 
sites examined, and also does not bind to microtubules. These 
findings suggest that like in AD, tau in SY5Y cells is hyper- 
phosphorylated, has minimal biological activity and accumu- 
lates in the cell cytoplasm. Hyperphosphorylation oftau similar 
to that in AD has also been observed in fetal rat and human 
brains [21,22]. However, immunocytochemical studies indicate 
that in contrast to AD, tau in the fetal brain is immobilized only 
in a relatively small number of neurons [23]. 
Of the total SY5Y-tau, about 80% is hyperphosphorylated 
at the Tau-1 epitope. Similarly high phosphorylation levels of 
the Tau-1 epitope have been previously demonstrated both in 
the soluble abnormally phosphorylated tau and the PHF-tau 
in AD [1,9]. Whether the degree of phosphorylation at Thr-231, 
Ser-396 and Ser-404 is as high as at the Tau-1 epitope, cannot 
be determined with the antibodies available to date. Further- 
more, it is not as yet known at what additional sites, if any, tau 
in SY5Y cells is phosphorylated. However, it appears that the 
hyperphosphorylation of SY5Y tau is sufficient to make it not 
bind to microtubules and accumulate in the living cell. 
Generally, endogenous tau in cells as well as tau in cells 
transfected with tau cDNA have been shown to decorate a
fibrous network, presumably microtubules [24-26]. In contrast, 
in the present study most of the hyperphosphorylated auis 
deposited in the perikarya of SY5Y cells and is not bound to 
the microtubule network. These findings uggest that the hyper- 
phosphorylation f tau might be the cause for both its accumu- 
lation and biological inactivity. The greater deposition of tau 
in SY5Y cells in nutrient deprived medium might be due to a 
decrease in pH. In vitro self-assembly of tau or its fragments 
has been reported at pH 4.5-5.5 [27-29]. 
Although most of the cytoplasmic tau was phosphorylated 
at the Tau-1 epitope, tau in the nucleus was not hyper- 
phosphorylated. Tau has been shown previously to colocalize 
with the nucleolus of several neuroblastoma cells [30]. There 
might be unknown regulatory mechanism that affect he local- 
ization of tau by phosphorylation. For example, certain pro- 
teins such as the nuclear factor of activated T-cells (NF-AT) 
and MAP kinase are known to be translocated to the nucleus 
depending upon their phosphorylation state [31,32]. 
The lack of microtubules in neurons with neurofibrillary 
tangles [33] as well as the in vitro inhibition of tau-mediated 
microtubule assembly by Alzheimer tau [11] suggests a poten- 
tial role of the hyperphosphorylated auin the microtubule 
defect in AD. In SY5Y cells, on the other hand, the microtubule 
system is apparently functional despite the presence of mostly 
hyperphosphorylated tau. A reason for this discrepancy might 
be that MAPlb, which is most probably expressed at higher 
levels in the readily dividing SY5Y cells than in the non-divid- 
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Fig. 5. Microtubule binding of MAPs from SY5Y cell extract. The 
200,000 x g extract of the SY5Y cells was incubated with taxol-stabi- 
lized microtubules and the MAPs bound or unbound to microtubules 
were examined by Western blots as described in section 2. For blots 
10% (20/.tg) of the pellet containing the microtubules and the bound 
proteins and 10% (100/~g) ofthe supernatant representing the unbound 
proteins were applied per lane, and the MAPs that were bound (b) or 
unbound (u) to the microtubules were studied with the appropriate 
antibodies; *Indicates alkaline phosphatase treatment of the im- 
munoblot before antibody application. Although MAPlb and MAP2 
bound to the microtubules, most of tau did not bind. 
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ing neurons of the brain, together with MAP2 compensates for 
the adverse effect of the hyperphosphorylated tau. Alterna- 
tively, SY5Y tau is probably not as hyperphosphorylated as 
AD tau to cause the breakdown of the microtubule system. The 
differences in the degree of tau phosphorylation between SY5Y 
cells and AD brain, are already indicated from its lack of 
phosphorylation at Ser-235 in the cultured cells. Nevertheless 
the present study shows the inactivity of hyperphosphorylated 
tau with microtubules and its accumulation i cultured cells i.e. 
outside of the human brain. 
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